Volume 6 Issue 2
Mar.  2015
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2015  >  6(2): 98-101
Song Jiyong, Du Guosheng, Zhu Zhidong, et al. Clinical application of thymalfasin in patients with severe pulmonary infection after liver transplantation[J]. ORGAN TRANSPLANTATION, 2015, 6(2): 98-101. doi: 10.3969/j.issn.1674-7445.2015.02.006
Citation: Song Jiyong, Du Guosheng, Zhu Zhidong, et al. Clinical application of thymalfasin in patients with severe pulmonary infection after liver transplantation[J]. ORGAN TRANSPLANTATION, 2015, 6(2): 98-101. doi: 10.3969/j.issn.1674-7445.2015.02.006
shu

Clinical application of thymalfasin in patients with severe pulmonary infection after liver transplantation

doi: 10.3969/j.issn.1674-7445.2015.02.006

  • Organ Transplant Institute of People's Liberation Army, the 309th Hospital of People's Liberation Army, Beijing 100091, China

More Information
  • Corresponding author: Du Guosheng, E-mail:duguosheng@medmail.com
  • Received Date: 2014-12-22
  • Publish Date: 2015-03-01
    Abstract
  •   Objective  To explore the efficacy and safety of thymalfasin in the treatment of severe pulmonary infection after liver transplantation.  Methods  Twenty seven patients who developed severe lung infection after undergoing liver transplantation in Organ Transplant Institute of the 309th Hospital of People's Liberation Army from January 2008 to May 2014 were enrolled in this study. According to whether the application of thymalfasin, the patients were divide into thymalfasin group(n=11) and control group(n=16). In the thymalfasin group, thymalfasin was administered via subcutaneous injection at a dose of 1.6 mg once daily for consecutive two weeks. In the control group, conventional anti-infection therapy was delivered. Ventilator time, duration of fever, the length of intensive care unit(ICU) stay and mortality were statistically compared between two groups. And the incidence of acute rejection (AR) was monitored.  Results  Ventilator time, duration of fever, length of ICU stay of patients in the thymalfasin group were significantly shortened compared with those in the control group (all in P < 0.05). There was no significant difference in the mortality between two groups. No clinical AR was observed in either group. No thymalfasin-related adverse event was found in the thymalfasin group.  Conclusions  Thymalfasin can improve the curative effect to anti-infection of patients with severe pulmonary infection after liver transplantation without the incidence of AR, which is efficacious and safe in the treatment of severe pulmonary infection.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    Feltracco P, Carollo C, Barbieri S, et al. Early respiratory complications after liver transplantation[J]. World J Gastroenterol, 2013, 19(48):9271-9281. doi: 10.3748/wjg.v19.i48.9271
    [2]
    Müller V, Kováts Z, Horváth G. Pulmonary infections following solid organ transplantation[J]. Orv Hetil, 2012, 153(23):899-903. doi: 10.1556/OH.2012.29395
    [3]
    Serafino A, Pierimarchi P, Pica F, et al. Thymosin α1 as a stimulatory agent of innate cell-mediated immune response[J]. Ann N Y Acad Sci, 2012(1270):13-20. http://www.researchgate.net/publication/232227940_Thymosin_1_as_a_stimulatory_agent_of_innate_cell-mediated_immune_response
    [4]
    Garaci E. Thymosin alpha1:a historical overview[J]. Ann N Y Acad Sci, 2007(1112):14-20. doi: 10.1196-annals.1415.039/
    [5]
    Roy R, Singh SM, Shanker A, et al. Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host:the molecular events involved and their inhibition by thymosin alpha-1[J]. Int J Immunopharmacol, 2000, 22(4):309-321. doi: 10.1016/S0192-0561(99)00087-9
    [6]
    Vogler MA, Teppler H, Gelman R, et al. Daily low-dose subcutaneous interleukin-2 added to single-or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function:results of a randomized controlled clinical trial (ACTG 248)[J]. J Acquir Immune Defic Syndr, 2004, 36(1):576-587. doi: 10.1097/00126334-200405010-00005
    [7]
    Nebbia G, Mattes FM, Sabin CA, et al. Differential effects of prednisolone and azathioprine on the development of human cytomegalovirus replication post liver transplantation[J]. Transplantation, 2007, 84(5):605-610. doi: 10.1097/01.tp.0000280555.08651.11
    [8]
    Ciancio A, Rizzetto M. Thymalfasin in the treatment of hepatitis B and C[J]. Ann N Y Acad Sci, 2010(1194):141-146. https://www.researchgate.net/publication/44662013_Thymalfasin_in_the_treatment_of_hepatitis_B_and_C
    [9]
    Garaci E, Pica F, Serafino A, et al. Thymosin α1 and cancer:action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012(1269):26-33. doi: 10.1111/j.1749-6632.2012.06697.x/references
    [10]
    Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumonia[J]. Expert Rev Respir Med, 2014, 8(5):587-596. doi: 10.1586/17476348.2014.927736
    [11]
    Song EY, Shin Y, Roh EY, et al. Serum HBsAg levels during peginterferon alpha-2a treatment with or without thymosin alpha-1 in HBeAg-positive chronic hepatitis B patients[J]. J Med Virol, 2011, 83(1):88-94. doi: 10.1002/jmv.v83:1
    [12]
    Sherman KE. Thymosin alpha 1 for treatment of hepatitis C virus:promise and proof[J]. Ann N Y Acad Sci, 2010(1194):136-140. https://www.researchgate.net/publication/44662012_Thymosin_a_1_for_treatment_of_hepatitis_C_virus_Promise_and_proof
    [13]
    刘洪涛, 彭龙开, 谢续标, 等.胸腺肽a1联合抗病毒药治疗肾移植术后巨细胞病毒肺炎[J].中国现代医学杂志, 2007, 17(22):2784-2786. http://d.wanfangdata.com.cn/Periodical/zgxdyxzz200722028

    Liu HT, Peng LK, Xie XB, et al. Combination therapy of thymosinal and antiviral drugs in kidney transplant recipients with cytomegalovirus pneumonia[J]. Chin J Mod Med, 2007, 17(22):2784-2786. http://d.wanfangdata.com.cn/Periodical/zgxdyxzz200722028
    [14]
    傅英梅, 徐战平.胸腺肽在肾移植术后巨细胞病毒肺炎治疗作用初探[J].国际医药卫生导报, 2005, 11(8):10-11. http://d.wanfangdata.com.cn/Periodical/gjyywsdb200508004

    Fu YM, Xu ZP. A preliminary study on thymosin in treatment of cytomegalovirus pneumonia after renal transplantation[J]. Int Med Health Guid News, 2005, 11(8):10-11. http://d.wanfangdata.com.cn/Periodical/gjyywsdb200508004
    [15]
    Ding JH, Wang LL, Chen Z, et al. The role of Tα1 on the infective patients after hematopoietic stem cell transplantation[J]. Int J Hematol, 2013, 97(2):280-283. doi: 10.1007/s12185-012-1208-5
    [16]
    Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway[J]. J EMBO Rep, 2005, 6(6):531-537. doi: 10.1038/sj.embor.7400433
    [17]
    Grottesi A, Sette M, Palamara T, et al. The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy. a possible model for its interaction with the lymphocyte membrane[J]. J Peptides, 1998, 19(10):1731-1738. doi: 10.1016/S0196-9781(98)00132-6
    [18]
    Hwang S, Kim KH, Song GW, et al. Peritransplant monitoring of immune cell function in adult living donor liver transplantation[J]. Transplant Proc, 2010, 42(7):2567-2571. doi: 10.1016/j.transproceed.2010.04.040
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (290) PDF downloads(14) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return